Food and Drug Administration (FDA) has asked India's Sun Pharmaceutical Industries Ltd (SUN.NS) to halt tests on one dose of an experimental dermatological drug due to the potential of blood clots, the company said on Tuesday.nnReporting by Rama Venkat in Bengaluru; Editing by Rashmi Aich
Concert Pharmaceuticals managed to keep hold of the breakthrough tag for its alopecia areata therapy, even though the approval of Eli Lilly’s rival gave the FDA second thoughts.